Evaluation of lipid services in the Republic of Ireland

Agar, Ruth; Prendergast, Meabh; Maher, Vincent

doi:10.1007/s11845-020-02187-6

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extent of lipid problems in Ireland is significant, and lipid management [4,6] and lipid services are inadequate [15,16]. The significance of untreated lipid disorders on population health cannot be overestimated [17,18], and early interventions could have far-reaching consequences on Irish lives and health care resource utilisation.…”

Section: Discussionmentioning

confidence: 99%

Abbreviated lipid guidelines for clinical practice

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Lipid disorders are now considered causal for atherosclerotic cardiovascular disease (ASCVD) which remains one of the most important contributors to morbidity and mortality in the developed world. Identification and early treatment of lipid disarrays remains the cornerstone of good clinical practice to prevent, halt and even reverse ASCVD. Guidelines for lipid management are imperative to help promote good clinical practice. Given the detail involved in comprehensive guidelines and the multiple areas of knowledge required by clinical practitioners, abbreviated, easy to understand, practical versions of guidelines are required to ensure dissemination of the most important information. The recent ESC lipid guidelines 2019 and the ESC guidelines on CVD prevention in clinical practice 2021 (1,2), provide an excellent detailed summary of all the latest evidence supporting lipid interventions that reduce ASCVD. Method We therefore developed a single-page document with hyperlinks to help practitioners gain easy access to practical information on lipid management. It has been developed for future electronic use in clinical practice. Conclusion It is presented here in a tabular format together with printable versions of the associated hyperlinks that provide the additional information required in decision making. It is hoped to audit the impact of this approach to help guide future ways of disseminating the latest clinical guideline updates.

show abstract

Section: Discussionmentioning

confidence: 99%

Abbreviated lipid guidelines for clinical practice

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, only 20 patients received ezetimibe (13 in combination) and nine patients were treated with other forms of non-statin LLT (PCSK9is, bile acid sequestrants, fish oils, or fibrates). Compared with other European countries, limited resources are available for dyslipidaemia management in Ireland, with only six designated lipid clinics and one specialist lipid nurse being available [18] and no structured programme in primary care for primary prevention and a limited secondary prevention programme implemented to date. Thus, the development of a structured care programme in primary care and education on guideline-directed lipid management in primary care and general secondary care clinics is of the utmost importance.…”

Section: Discussionmentioning

confidence: 99%

The DA VINCI study: is Ireland achieving ESC/EAS guideline–directed LDL-C goals?

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background The EU-wide, cross-sectional observational study of lipid-lowering therapy (LLT) use in secondary and primary care (DA VINCI) assessed the proportion of patients achieving low-density lipoprotein cholesterol (LDL-C) goals recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines and provided an insight into regional use of LLT in Europe, including Ireland. Aims This analysis focuses on data from patients in Ireland who participated in the DA VINCI study. Methods The DA VINCI study enrolled patients receiving LLT at primary and secondary care sites across 18 European countries between June 2017 and November 2018. The study assessed the achievement of risk-based 2016 and 2019 ESC/EAS LDL-C goals. This subgroup analysis aimed to evaluate LDL-C goal attainment in an Irish cohort of primary and secondary care patients. Results In total, 198 patients from Ireland were enrolled from three primary care and three secondary care centres. Most patients were White and male, and were receiving moderate- or high-intensity statin therapy (most frequently atorvastatin or rosuvastatin). Few patients (< 10%) were receiving combination therapy of statin and ezetimibe. Approximately 60% of patients achieved their 2016 ESC/EAC LDL-C goals while less than half the patients achieved their 2019 ESC/EAS goals. Approximately half of secondary prevention patients achieved their 2016 ESC/EAS goals and only 20% of secondary prevention patients achieved their 2019 ESC/EAS goals. Conclusions These results highlight the disparity between dyslipidaemia management in clinical practice in Ireland and guideline recommendations. Trial registration ENCePP; EU PAS 22,075; date registered 06 February 2018.

show abstract

Evaluation of lipid services in the Republic of Ireland

Cited by 2 publications

References 21 publications

Abbreviated lipid guidelines for clinical practice

Abbreviated lipid guidelines for clinical practice

The DA VINCI study: is Ireland achieving ESC/EAS guideline–directed LDL-C goals?

Contact Info

Product

Resources

About